CELCUITY INC. - COMMON STOCK

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

04 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

20 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

28 Feb 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

22 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

20 Feb 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

06 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

01 Dec 2023 10:02:45 By Nasdaq GlobeNewswire

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

22 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

13 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

06 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

01 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

Celcuity to Host Virtual Science Day for Investors

07 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

22 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

22 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

10 Aug 2023 15:04:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

03 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

31 Jul 2023 07:00:01 By Nasdaq GlobeNewswire